Mirum Pharmaceuticals, Inc.

DB:08D Stock Report

Market Cap: €1.7b

Mirum Pharmaceuticals Valuation

Is 08D undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 08D when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 08D (€35.8) is trading below our estimate of fair value (€228.27)

Significantly Below Fair Value: 08D is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 08D?

Other financial metrics that can be useful for relative valuation.

08D key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue7.2x
Enterprise Value/EBITDA-21.5x
PEG Ration/a

Price to Sales Ratio vs Peers

How does 08D's PS Ratio compare to its peers?

The above table shows the PS ratio for 08D vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average8.7x
BIO3 Biotest
1.4x-4.1%€1.4b
FYB Formycon
15.5x32.5%€944.6m
MOR MorphoSys
10.2xn/a€2.5b
2INV 2invest
7.8xn/a€60.4m
08D Mirum Pharmaceuticals
7.1x25.0%€1.9b

Price-To-Sales vs Peers: 08D is good value based on its Price-To-Sales Ratio (7.1x) compared to the peer average (8.7x).


Price to Earnings Ratio vs Industry

How does 08D's PE Ratio compare vs other companies in the DE Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a34.8%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a34.8%
n/an/an/a
No more companies

Price-To-Sales vs Industry: 08D is good value based on its Price-To-Sales Ratio (7.1x) compared to the European Biotechs industry average (8.8x).


Price to Sales Ratio vs Fair Ratio

What is 08D's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

08D PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7.1x
Fair PS Ratio5x

Price-To-Sales vs Fair Ratio: 08D is expensive based on its Price-To-Sales Ratio (7.1x) compared to the estimated Fair Price-To-Sales Ratio (5x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 08D forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€35.80
€54.31
+51.7%
17.6%€65.05€35.73n/a11
Sep ’25€37.40
€54.31
+45.2%
17.6%€65.05€35.73n/a11
Aug ’25€37.00
€52.82
+42.8%
19.7%€65.59€36.03n/a11
Jul ’25€31.40
€53.29
+69.7%
19.6%€66.28€36.41n/a11
Jun ’25€22.40
€44.36
+98.0%
22.2%€60.99€28.65n/a11
May ’25€23.00
€46.05
+100.2%
24.9%€67.79€31.07n/a11
Apr ’25€23.00
€45.08
+96.0%
26.0%€66.25€30.36n/a10
Mar ’25€26.20
€43.56
+66.2%
25.3%€63.67€30.45n/a10
Feb ’25€24.00
€44.31
+84.6%
25.6%€58.96€30.40n/a10
Jan ’25€27.60
€44.24
+60.3%
25.4%€58.62€30.23n/a10
Dec ’24€29.20
€49.98
+71.2%
25.5%€71.28€33.81n/a10
Nov ’24€25.40
€54.12
+113.1%
22.7%€72.21€35.64n/a7
Oct ’24€29.60
€55.54
+87.6%
29.9%€78.80€32.83€34.805
Sep ’24€24.20
€51.95
+114.7%
33.3%€77.24€32.18€37.404
Aug ’24€23.20
€51.29
+121.1%
31.9%€74.77€31.91€37.004
Jul ’24€22.40
€49.72
+122.0%
33.5%€73.99€31.06€31.407
Jun ’24€24.40
€46.50
+90.6%
36.7%€73.31€27.15€22.408
May ’24€23.20
€46.50
+100.4%
36.7%€73.31€27.15€23.008
Apr ’24€20.80
€48.52
+133.3%
37.3%€78.00€28.19€23.008
Mar ’24€21.80
€48.54
+122.7%
37.4%€78.61€28.07€26.208
Feb ’24€21.20
€49.26
+132.4%
37.9%€78.25€27.95€24.008
Jan ’24€17.80
€51.50
+189.3%
36.9%€82.78€28.22€27.608
Dec ’23€17.60
€53.66
+204.9%
36.7%€84.52€28.81€29.208
Nov ’23€22.40
€56.82
+153.7%
35.1%€88.31€31.11€25.408
Oct ’23€21.00
€54.67
+160.3%
31.8%€77.42€31.17€29.608

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies